Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Beijing Glyexo Gene Technology Co. Ltd. is active in the Biotechnology & Pharmaceuticals technology area with a portfolio that currently shows 1 pending office action. This 1 pending office action represents the only active prosecution matter for the company. The examiner assigned to this case is LUSI, ELLIS FOLLETT, who is the busiest examiner for the portfolio. With 1 busiest examiner pending action, the company's immediate progress in the Biotechnology & Pharmaceuticals sector is tied to this interaction.
The portfolio's prosecution is centralized, involving 1 distinct examiner and 1 distinct art unit. This suggests that the company's genetic innovations are concentrated within a specific niche of the pharmaceutical industry. By operating within 1 distinct art unit, the company only needs to navigate the specific standards and timelines of that unit. The presence of 1 distinct examiner means that the company can focus its resources on a single relationship rather than managing multiple examiner styles. This 1 pending office action is the sole focus of the company's current efforts to secure its intellectual property assets.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LUSI, ELLIS FOLLETT | 1 | 64.0% | +53.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17864572 | LECTIN-MACROMOLECULE CARRIER COUPLING COMPLEX FOR SEPARATING GLYCOSYLATED EXOSOME IN CLINICAL SAMPLE | LUSI, ELLIS FOLLETT | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17864572 | LECTIN-MACROMOLECULE CARRIER COUPLING COMPLEX FOR SEPARATING GLYCOSYLATED EXOSOME IN CLINICAL SAMPLE | LUSI, ELLIS FOLLETT | — |
| Art Unit | Apps |
|---|---|
| 1600 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17864572 | LECTIN-MACROMOLECULE CARRIER COUPLING COMPLEX FOR SEPARATING GLYCOSYLATED EXOSOME IN CLINICAL SAMPLE | LUSI, ELLIS FOLLETT | 1600 | §102§103§112Other | Non-Final OA | — | Pending | Jul 14, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBeijing Glyexo Gene Technology Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Ellis Follett Lusi has the most, with 1 of Beijing Glyexo Gene Technology Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
